Opendata, web and dolomites

LIBSED SIGNED

Libiguins: a remedy for the treatment of sexual dysfunctions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIBSED project word cloud

Explore the words cloud of the LIBSED project. It provides you a very rough idea of what is the project "LIBSED" about.

drug    commercialization    intercourse    plan    mins    accordingly    life    exerts    treatments    libiguin    controls    dic2024    prepare    limited    erectile    couple    natural    lies    instrument    criticism    planning    cns    ejaculation    efferents    onset    date    induce    integrative    coupled    human    sexual    inhibitors    standard    behavior    integration    15    ed    guide    premature    clinical    practiced    neuronal    inability    turn    tackle    first    sd    worldwide    preclinical    auditory    ethnopharmacological    uniqueness    substantial    quality    pde    business    performed    groups    commercialisation    billion    visual    sme    stimuli    trial    socioeconomic    promise    strategies    men    burden    protocol    dicot    care    effect    slow    erection    plant    sex    utilises    pe    medicine    afferent    wants    dysfunction    candidate    tactile    efficacy    options    supporting    types    action    compound    implications    ethnic    delayed    treatment    serious    spinal    time    data    give   

Project "LIBSED" data sheet

The following table provides information about the project.

Coordinator
DICOT AB 

Organization address
address: DAG HAMMARSKJOLDS VAG 30
city: UPPSALA
postcode: 752 37
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DICOT AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

This project will develop a business plan to guide clinical development and commercialization strategies for DIC2024, a novel drug candidate for the treatment of the common types of sexual dysfunction (SD): erectile dysfunction (ED) and premature ejaculation (PE) that affects 2 billion men worldwide. SD has serious implications on quality of life and is a significant socioeconomic burden. Current standard-of-care includes the use of PDE-5 inhibitors for ED and limited options for PE. The available treatments do not give long effect duration and therefore a major criticism is their inability to facilitate a more natural sex life that does not require planning every time a couple wants to have sexual intercourse. This is also related to delayed efficacy (15-60 mins) when using PDE-5 inhibitors. Accordingly, Dicot has developed DIC2024 that utilises a principle from a plant called Libiguin. Libiguin exerts a slow-onset, long-term action on the CNS’s integrative control systems for sexual behavior, which in turn controls spinal neuronal efferents that control erection and sexual behaviour. It also includes integration of afferent stimuli (tactile, visual, auditory). DIC2024’s uniqueness therefore lies in its potential to induce long term effects to tackle SD. The preclinical work performed to date includes development of the production protocol and studies to characterize the compound. Coupled with ethnopharmacological data (traditional medicine practiced by ethnic groups) supporting clinical use of Libiguin in men with SD, there is significant promise for the use of DIC2024 in the treatment of ED and PE. The proposed project will further prepare DIC2024 for a first-in-human clinical trial. SME Instrument funding will allow Dicot to take substantial steps along the path of commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIBSED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIBSED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More